Markers of oxidative damage have been detected in brain tissue from patients with Alzheimer disease (AD) and other neurodegenerative disorders. These findings implicate oxidative injury in the neurodegenerative process, but whether oxidative stress is a cause or a consequence of neurotoxicity remains unclear. We used a *Drosophila* model of human tauopathies to investigate the role of oxidative stress in neurodegeneration. Genetic and pharmacological manipulation of antioxidant defense mechanisms significantly modified neurodegeneration in our model, suggesting that oxidative stress plays a causal role in neurotoxicity. We demonstrate that the JNK signaling pathway is activated in our model, which is in agreement with previous findings in AD tissue. Furthermore, we show that the extent of JNK activation correlates with the degree of tau-induced neurodegeneration. Finally, our findings suggest that oxidative stress acts not to promote tau phosphorylation, but to enhance tau-induced cell cycle activation. In summary, our study identifies oxidative stress as a causal factor in tau-induced neurodegeneration in *Drosophila*.

**Introduction**

Alzheimer disease (AD), the most prevalent form of dementia, is a devastating and ultimately fatal neurodegenerative disorder characterized by progressive loss of memory and cognition. Although early-onset familial forms of the disease have been identified, most AD cases are sporadic, and the major risk factor for the disease is age (1). A prominent hypothesis regarding the aging process proposes that the accumulation of oxidative damage on macromolecules is the main cause of cellular senescence (2). Oxidative stress results from an imbalance in aerobic metabolism and poses a serious threat to cellular homeostasis. Highly reactive oxygen species oxidize lipids, proteins, and DNA, leading to tissue damage and cell death. To counteract the deleterious effects of ROS, organisms have developed a number of antioxidant defense mechanisms (3).

Major support for the oxidative stress theory of aging has come from genetic studies showing that manipulation of antioxidant defense pathways affects longevity. For instance, the consecutive enzymatic activities of superoxide dismutase (SOD) and catalase are critical to eliminating superoxide anion, an extremely toxic ROS, and mutation or downregulation of these enzymes has been associated with reduced longevity in *Drosophila* (4–7). Conversely, increasing SOD1 or SOD2 levels can extend lifespan in *Drosophila*, and catalase overexpression promotes longevity in both flies and mice (8–11). Similar genetic manipulations have highlighted the importance of another line of defense in which the cyclic oxidation and reduction of thioredoxin by thioredoxin peroxidases (Tpx) and reductases (Trxr) is ultimately used for the breakdown of hydrogen peroxide (12–15).

While endogenous antioxidant pathways can protect against low levels of ROS, higher doses or persistent injury can trigger cell death. It has been well documented that oxidative stress can induce apoptosis through sustained activation of the JNK signaling pathway (3, 16).

In addition to its likely role in senescence, oxidative stress has also been implicated in neurodegeneration. The brain appears to be particularly sensitive to oxidative injury, and there is substantial evidence demonstrating the presence of oxidative damage in postmortem brain tissue derived from patients with age-related neurodegenerative disorders, including AD (17, 18). Notably, markers for oxidized lipids and proteins accumulate in regions that are particularly affected by neurodegeneration (19, 20). Whether these markers are a mere secondary consequence of the disease or oxidative stress plays a fundamental role in neurodegeneration is a question that remains open.

Another characteristic feature of several neurodegenerative disorders, including AD, is the ectopic expression of cell cycle markers (21–23). The presence of cell cycle markers in neurodegenerative disease tissue raised the possibility that aberrant activation of the cell cycle machinery in postmitotic neurons could be lethal and contribute to neurodegeneration. Although a connection has been established between oxidative injury and cell cycle induction, it is unclear whether oxidative stress contributes to cell cycle activation during progressive neurodegeneration (24).

In this study, we used a *Drosophila* model relevant to human neurodegenerative diseases, including AD, to investigate the role of oxidative stress in neurodegeneration. A group of neurodegenerative disorders, including AD, are characterized pathologically by the deposition of intracellular aggregates containing abnormally phosphorylated forms of the microtubule-binding protein tau (25). These disorders are often termed *tauopathies*. Mutations in the tau gene itself have been identified in familial forms of frontotemporal dementias (26), demonstrating that abnormalities in tau can directly mediate neurodegeneration. Consistent with this hypothesis, expression of wild-type and mutant forms of human tau in the *Drosophila* nervous system results in a neurodegenerative phenotype that recapitulates several characteristics of human tauopathies (27, 28). This model provides an in vivo system useful for dissecting the...
molecular mechanisms underlying neurodegeneration, and we have used it to address the role of oxidative stress in neuronal cell death. We have employed genetic and pharmacological approaches to modify the phenotype of transgenic flies that express a disease-related mutant form of human tau (tau\(^{R406W}\)) in a panneuronal pattern. Our results strongly suggest that oxidative stress plays a causal role in tau-induced neurodegeneration. We also found that tau-induced toxicity is accompanied by activation of the JNK signaling pathway. Interestingly, the extent of JNK pathway activation directly correlated with neurotoxicity levels. Further analysis indicated that oxidative stress did not promote tau phosphorylation in our model and suggested that oxidative injury may trigger apoptosis by intensifying tau-mediated cell cycle activation.

Results
Oxidative stress mediates neurotoxicity in a Drosophila tauopathy model. To determine whether oxidative damage plays an active role in neurodegeneration, we first tested whether genetic downregulation of antioxidant defense pathways would enhance tau-induced toxicity. Overexpression of mutant tau (tau\(^{R406W}\)) in the fly brain results in a progressive neurodegenerative phenotype characterized by histological abnormalities, including degeneration of neurons in the cortex and neuropil vacuolization (27), that can be visualized in standard histological preparations. The cell bodies of neurons and glia occupy the outer cortical layer of the brain, which is basophilic and can be distinguished after H&E staining by a dark purple color. Processes of neurons and glia are located in the inner neuropil region, which is eosinophilic and stains pink or light purple following H&E processing (Figure 1, A–D, and Supplemental Figures 1, A–F, and 2, A and B; supplemental material available online with this article; doi:10.1172/JCI28769DS1). The brains of control flies were well preserved at 10 days of age (Figure 1A), but degenerative changes were apparent in both the cortex and the neuropil of tau\(^{R406W}\) transgenic flies by day 10 (Figure 1B and Supplemental Figure 1, A and B) (27). Heterozygosity for a Trxr-null allele (Trxr\(^{-}\)) that removes both the mitochondrial and cytoplasmic forms of the enzyme (15) enhanced tau toxicity in the brain as evidenced by an increase in cortex and neuropil vacuolization (Figure 1C and Supplemental Figure 1, C and D). Similarly, reduced gene dosage of mitochondrial Sod2 in tau transgenic flies heterozygous for a null allele (Sod2\(^{n283}\)) (4) also enhanced tau-induced neurodegeneration (Figure 1D and Supplemental Figure 1, E and F). Quantification of the total number of vacuoles present in the cortex and neuropil of 10-day-old transgenic animals and controls revealed that brain vacuolization in tau\(^{R406W}\)-expressing flies heterozygous for Trxr\(^{-}\) or for Sod2\(^{n283}\) was significantly increased by greater than 2-fold and 3-fold, respectively, compared with that of tau\(^{R406W}\) transgenic animals (Figure 1E).

Tau-induced neurodegeneration occurs by an apoptotic cell death mechanism in our model (27–29). While no TUNEL-positive cells were detected in the brains of 10-day-old controls (Figure 2A), modest numbers of apoptotic nuclei were present in age-matched tau transgenic flies (Figure 2B) (27). Significantly increased numbers of TUNEL-positive cells were present in tau transgenic animals heterozygous for Trxr\(^{-}\) (Figure 2C) or for Sod2\(^{n283}\) (Figure 2D). Quantitative analysis revealed a greater than 2-fold increase in the number of apoptotic cells compared with that of tau\(^{R406W}\) transgenics (Figure 2E). In contrast, heterozygosity for either Trxr\(^{-}\) or Sod2\(^{n283}\) in the absence of tau\(^{R406W}\) expression was not associated with neurodegeneration. In fact, Sod2\(^{n283}\) and Trxr\(^{-}\) heterozygous flies were indistinguishable from controls at day 10, with respect to gross brain morphology (compare Supplemental

**Figure 1**
Partial inactivation of antioxidant pathways enhances neurodegeneration in a Drosophila tauopathy model. (A–D) Frontal brain sections of 10-day-old flies were stained with H&E. Neurodegeneration was not detected in control flies (A) but was evident in transgenic flies expressing tau\(^{R406W}\) (B). Tau-induced toxicity was enhanced by removing 1 functional copy of Trxr in tau\(^{R406W}\) transgenic flies heterozygous for the Trxr\(^{-}\)-null allele (C) and by reducing gene dosage of mitochondrial Sod2 in tau\(^{R406W}\) transgenic flies heterozygous for a null allele (Sod2\(^{n283}\)) (D). Vacuolar degeneration was observed in the neuropil (arrows) and in the cortex (arrowheads). Scale bar: 20 μm. (E) Tau-induced toxicity was significantly enhanced by genetic downregulation of Trxr (**P < 0.001) and Sod2 (**P < 0.001) activities. Neurodegeneration was assessed by quantification of vacuoles with diameter greater than 3 μm in the brains of 10-day-old flies. Data points represent the mean ± SEM. In Figures 1, 2, and 7, genotypes are as follows: control, elav-GAL4/+; Trxr\(^{+}\); elav-GAL4/Txr\(^{−}\); Sod2\(^{n283}\); elav-GAL4/+; Sod2\(^{n283}\); elav-GAL4/+; tau\(^{R406W}\); elav-GAL4/Txr\(^{−}\); Sod2\(^{n283}\); elav-GAL4/+; tau\(^{R406W}\) + Trxr\(^{−}\); elav-GAL4/Txr\(^{−}\); Sod2\(^{n283}\); elav-GAL4/+; Sod2\(^{n283}\); tau\(^{R406W}\); elav-GAL4/+; tau\(^{R406W}\) + Sod2\(^{n283}\); elav-GAL4/+; Sod2\(^{n283}\); tau\(^{R406W}\); and elav-GAL4/+; Sod2\(^{n283}\); tau\(^{R406W}\).
Figure 2

Downregulation of Sod2 or of Trxr antioxidant activities increases neuronal cell death in a Drosophila tauopathy model. (A–D) TUNEL assay in 10-day-old transgenic fly brains. Apoptotic cells, absent in control animals (A), were identified by TUNEL staining (arrows) in the brains of tauR406W transgenic flies (B) and were found to be more abundant in tauR406W flies heterozygous for TrxrΔ1 (C) and for Sod2n283 (D). Scale bar: 10 μm. (E) Neurodegeneration was significantly enhanced by partial inactivation of Trxr (**P < 0.001) and Sod2 (***P < 0.001) activities. The number of TUNEL-positive cells in the brains of 10-day-old tauR406W-expressing flies was compared with that in age-matched controls, in Sod2n283 and TrxrΔ1 heterozygous animals, and in tauR406W flies heterozygous for either Sod2n283 or TrxrΔ1. Data points represent the mean ± SEM. (F–K) Tau-induced toxicity was associated with neuronal cell death. TUNEL-positive cells (green fluorescence) were found to coexpress the neuronal cell marker elav (red fluorescence) (F–H) and did not colocalize with repo-positive glial cells (red fluorescence) (I–K). Arrowheads mark the location of TUNEL-positive cells. Scale bars: 5 μm.

was not the added effect of 2 toxicities but was instead the result of synergistic effects between tau and increased oxidative stress.

To test whether decreasing oxidative stress can rescue neurodegeneration, we coexpressed tauR406W with Sod2 (30), which led to a 50% decrease in the number of TUNEL-positive cells found in tau transgenics (Figure 3A). In addition, coexpression of tauR406W with Tpx1 (14) resulted in a greater than 60% reduction of brain apoptosis compared with tau alone (Figure 3A). To determine whether the tau neurodegenerative phenotype is amenable to pharmacological intervention, we fed tauR406W-expressing flies and control flies for 10 days with 2 different levels of vitamin E. We used α-tocopherol, a vitamin E isoform that is the most powerful naturally occurring antioxidant known to date (31). Control cohorts within each genotype were fed with soybean oil solvent alone. Neurodegeneration associated with expression of tauR406W was significantly suppressed by treatment of adult flies with 0.5 mM and 1.5 mM of vitamin E, as evidenced by 30% and 50% declines in the number of TUNEL-positive cells, respectively, when compared with tau transgenic flies fed with solvent only (Figure 3B). Treatment with vitamin E did not influence cell death in control animals (Figure 3B). In addition, Western blot analysis revealed that the levels of tau protein were not altered by feeding flies with vitamin E (data not shown). This result indicates that the decrease in toxicity observed in drug-fed tauR406W flies is not caused by a downregulation of tau transgene expression and suggests a neuroprotective role for vitamin E. Overexpression of antioxidant enzymes and treatment with vitamin E were not sufficient to completely reduce neuronal cell death to the levels observed in control flies, but they significantly rescued neurotoxicity in tauR406W transgenic animals (Figure 3, A and B). Taken together, these observations suggest that tau-induced neurodegeneration is, at least in part, mediated by oxidative damage.

To determine whether tau-expressing flies have altered susceptibility to oxidative injury, we treated tauΔR406W transgenic flies and controls with the drug paraquat, a widely used free radical generator that can increase ROS levels in vivo (32). Administration of a total of 30 mM paraquat over 48 hours induced 30% lethality in control flies (Figure 4). The tauR406W transgenic animals were significantly more sensitive to paraquat than controls, exhibiting a 70% mortality rate (Figure 4). There was no significant lethality associated with either tau transgenics or control flies after 48 hours of feeding on drug-free food (Figure 4).

Figure 2, A and B, with Figure 1A), total number of vacuoles (Figure 1E), and neuronal cell death (Figure 2E). Notably, in older flies heterozygous for Sod2n283 or for TrxrΔ1, brain vacuolization and cell death were still comparable to that of age-matched control flies (Supplemental Figure 2, C and D).

To identify the nature of the apoptotic cells identified in tauR406W-expressing flies, brain sections of 10-day-old transgenic flies were costained with TUNEL and with antibodies recognizing either a neuronal cell marker (elav) or a glial cell marker (repo) (Figure 2, F–K). TUNEL-positive cells also expressed elav (Figure 2, F–H). In contrast, there was no evidence of TUNEL-positive cells colocalizing with repo-expressing cells (Figure 2, I–K). These observations suggest that the large majority of apoptotic cells identified in the brains of tau transgenic flies are neurons, suggestive of a cell-autonomous mechanism of tau-induced cell death.

Taken together, histological analysis and quantification of neuronal apoptosis demonstrated that the downregulation of antioxidant defense pathways significantly enhanced tau neurotoxicity. Moreover, the absence of neurodegeneration in Sod2n283 and TrxrΔ1 heterozygous flies suggested that this enhancement

Figure 2 Downregulation of Sod2 or of Trxr antioxidant activities increases neuronal cell death in a Drosophila tauopathy model. (A–D) TUNEL assay in 10-day-old transgenic fly brains. Apoptotic cells, absent in control animals (A), were identified by TUNEL staining (arrows) in the brains of tauR406W transgenic flies (B) and were found to be more abundant in tauR406W flies heterozygous for TrxrΔ1 (C) and for Sod2n283 (D). Scale bar: 10 μm. (E) Neurodegeneration was significantly enhanced by partial inactivation of Trxr (**P < 0.001) and Sod2 (***P < 0.001) activities. The number of TUNEL-positive cells in the brains of 10-day-old tauR406W-expressing flies was compared with that in age-matched controls, in Sod2n283 and TrxrΔ1 heterozygous animals, and in tauR406W flies heterozygous for either Sod2n283 or TrxrΔ1. Data points represent the mean ± SEM. (F–K) Tau-induced toxicity was associated with neuronal cell death. TUNEL-positive cells (green fluorescence) were found to coexpress the neuronal cell marker elav (red fluorescence) (F–H) and did not colocalize with repo-positive glial cells (red fluorescence) (I–K). Arrowheads mark the location of TUNEL-positive cells. Scale bars: 5 μm.
In summary, we found that both genetic and pharmacological manipulation of antioxidant defense mechanisms can modify tau toxicity in vivo. In particular, the fact that oxidative stress suppressors had a protective effect on neurotoxicity strongly suggests that oxidative damage plays a causal role in tau-induced neurodegeneration.

Oxidative damage does not act by altering tau phosphorylation. One of the major pathological features of AD and other tauopathies is the accumulation of abnormally phosphorylated forms of tau in the brains of affected individuals (25). Phosphorylation of tau at serines and threonines that are followed by a proline residue (SP/TP sites) is particularly characteristic of neurodegenerative disease tissue (33). Antibodies AT8, AT100, AT180, TG3, and PHF1, which recognize tau phosphorylated at SP/TP sites, specifically reacted with the brains of tauR406W-expressing flies but not with those of control flies (Figure 5A) (27–29). Expression of tauR406W in flies heterozygous for the TrxrA1-null mutation or for the Sod2n283-null allele did not significantly change the levels of phosphorylated tau in the brains of transgenic flies. The tested animals also expressed equivalent levels of total tau and of Tau1, which recognizes an unphosphorylated form of tau (Figure 5A).

Our results indicate that, despite enhancing neurodegeneration, increased oxidative stress did not appear to modify tau phosphorylation. This observation suggested that increased oxidative damage does not act to promote tau phosphorylation in our model.

The fact that aberrantly phosphorylated tau accumulates during neurodegeneration suggests that phosphorylation may contribute to toxicity. Support for this hypothesis has recently been provided by a number of studies (28, 29, 34, 35). Moreover, in our laboratory, expression of mutant tau constructs in Drosophila revealed a direct correlation between phosphorylation and tau-induced degeneration (Steinhilb et al., unpublished observations; ref. 35).

In one of these constructs, designated tauE14, 14 disease-associated SP/TP phosphorylation sites were mutated to glutamate to mimic a direct correlation between phosphorylation and tau-induced toxicity. Expression of mutant tau constructs in animals also expressed equivalent levels of total tau and of Tau1, which specifically reacted with the brains of tauR406W-expressing flies. The tested flies had a protective effect on neurotoxicity strongly suggests that oxidative stress suppressors could be used to evaluate neurotoxicity in controls and in tauR406W transgenic coexpressing either β-gal (control transgene), Tpx1, or Sod2. Genotypes are as follows: control, elav-GAL4/+; tauR406W+ β-gal, elav-GAL4/+; UAS-lacZ+, UAS-tauR406W+/+, tauR406W+/+, Tpx1, elav-GAL4/+; UAS-Tpx1/+, UAS-tauR406W/+; and tauR406W+/+, Sod2, elav-GAL4/+; UAS-Sod2+/+, UAS-tauR406W/+.

(B) Administration of vitamin E for 10 days after eclosion suppressed tau-induced neurodegeneration. TUNEL assay quantification measured apoptosis in the brains of tauR406W-expressing flies and control flies fed with soybean oil solvent (control) or with the indicated doses of vitamin E. Tau-induced neurodegeneration was significantly suppressed in tauR406W transgenic flies by feeding with 0.5 mM (**P < 0.001) or 1.5 mM (**P < 0.001) of vitamin E compared with feeding with solvent only. Treatment of tauR406W transgenic flies with vitamin E did not completely abolish neuronal cell death, since toxicity was still significantly higher (P < 0.001) than in control flies. Error bars indicate ± SEM. Genotypes are as follows: control, elav-GAL4/+; and tauR406W, elav-GAL4/+; UAS-tauR406W/+.

Figure 3
Genetic and pharmacological upregulation of antioxidant defenses suppresses tau-induced toxicity in vivo. (A) Neurodegeneration was significantly reduced by coexpression of tauR406W with Tpx1 (**P < 0.001) or with Sod2 (**P < 0.001). Neuronal cell death in tauR406W transgenic flies that have increased expression of Tpx1 (P < 0.05) or of Sod2 (P < 0.01) was still significantly higher than in controls, indicating that tau-induced neurotoxicity was not completely rescued by these increased antioxidant activities. Quantification of TUNEL-positive cells in the brains of 10-day-old flies was used to evaluate neurotoxicity in controls and in tauR406W transgenics coexpressing either β-gal (control transgene), Tpx1, or Sod2. Genotypes are as follows: control, elav-GAL4/+; tauR406W+ β-gal, elav-GAL4/+; UAS-lacZ+, UAS-tauR406W+/+, tauR406W+/+, Tpx1, elav-GAL4/+; UAS-Tpx1/+, UAS-tauR406W/+; and tauR406W+/+, Sod2, elav-GAL4/+; UAS-Sod2+/+, UAS-tauR406W/+.

Figure 4
TauR406W transgenic flies are more sensitive to oxidative injury than age-matched controls. One-day-old flies were exposed to no drug or to 30 mM paraquat, and survival was scored after 48 hours. Compared with use of drug-free medium, administration of paraquat resulted in significant lethality for control flies (**P < 0.001) and for tauR406W transgenic flies (**P < 0.001). TauR406W-expressing flies were significantly more sensitive to 30 mM paraquat (P < 0.001) than controls. Genotypes are as follows: control, elav-GAL4/+; and tauR406W, elav-GAL4/+; UAS-tauR406W/+.
sion of tau\(^{E14}\) in flies heterozygous for Trxr\(^{Δ}\) resulted in a 2-fold increase in the number of TUNEL-positive neurons compared with that in transgenic flies expressing tau\(^{E14}\) alone (Figure 5B). Expression of tau\(^{E14}\) in animals heterozygous for Sod2\(^{1}\) led to a 2.5-fold increase in brain apoptosis compared with that in tau\(^{E14}\) transgenics (Figure 5B). Thus, neurodegeneration mediated by tau\(^{E14}\) was significantly enhanced by a genetic increase in oxidative stress levels. Taken together, our results strongly suggest that oxidative damage does not act by influencing tau phosphorylation.

**JNK pathway activation correlates with tau-induced neurotoxicity.**

The induction of stress-activated protein kinase cascades, such as the JNK signaling pathway, is one of the best-characterized responses to oxidative damage (3, 36). To determine whether JNK pathway activation correlated with tau-induced neurodegeneration in our model, we first used TUNEL quantification to assess neuronal cell death in control flies and in flies that expressed different forms of tau (Figure 6A). This analysis confirmed that wild-type tau (tau\(^{WT}\)) is moderately toxic, the disease-associated mutant tau\(^{R406W}\) has increased toxicity, and the pseudophosphorylated mutant tau\(^{E14}\) is even more toxic (Figure 6A) (27, 35). To measure JNK pathway activation, we immunostained the brains of 10-day-old adult flies with an antibody that recognizes activated JNK protein. Minimal immunoreactivity for active JNK was present in the cortex of control flies (Figure 6B) while active JNK accumulated in cortical areas, showing histological evidence of neurodegeneration in all the tau transgenic flies (tau\(^{E14}\) is depicted in Figure 6C). We additionally employed the puc-lacZ (puc-lacZ) reporter system, which has been commonly used to monitor JNK pathway activation in Drosophila. The puc gene encodes a phosphatase that inactivates JNK and other MAPK family members and is a well-established transcriptional target of JNK signaling in Drosophila (37). Brains from transgenic flies carrying the puc-lacZ reporter alone or with various tau transgenes were immunostained at 10 days after eclosion with an antibody against β-gal. Reporter activity was minimal in control flies (Figure 6, D and F) while numerous cortical cells were β-gal–positive in tau transgenic animals (Figure 6, E and F). Quantification of JNK activity in the cortex of transgenic animals revealed that the number of β-gal–positive neurons was increased by over 2-fold for tau\(^{WT}\), 6-fold for tau\(^{R406W}\), and 9-fold for tau\(^{E14}\) flies compared with control flies that did not express human tau (Figure 6F). These results showed a close correlation between JNK pathway activation and the degree of neurotoxicity associated with different tau transgenes. Furthermore, β-gal–positive staining was identified in cells that also expressed the neuronal cell marker elav (Figure 6, G–I) but not in repo-positive glial cells (Figure 6, J–L), suggesting that in our tauopathy model, JNK activation occurs mostly in neurons.

**Oxidative stress enhances cell cycle activation.**

We have recently shown that cell cycle activation mediates neurodegeneration in tau transgenic flies (35). To determine whether oxidative stress promotes tau-induced neurodegeneration by activating the cell cycle, brains of tau\(^{R406W}\)-expressing flies aged for 10 days were immunostained with an antibody against the proliferating cell nuclear antigen (PCNA), an S-phase marker abnormally reexpressed in human degenerative disease tissue (22) as well as in tau transgenic flies (35). No PCNA immunostaining was detected in control animals (Figure 7A), but multiple foci were present in tau\(^{R406W}\) transgenic brains (Figure 7B). The tau\(^{R406W}\)-expressing flies haploinsufficient for Trxr (Figure 7C) or Sod2 (Figure 7D) exhibited substantially higher levels of PCNA staining in their brains than transgenic animals expressing tau\(^{R406W}\) alone (Figure 7B). PCNA staining accumulated in areas of neurodegeneration (Figure 7, B–D). Quantification of PCNA immunostaining revealed that the number of PCNA-positive foci found in the brains of tau\(^{R406W}\) transgenic flies increased by more than 2-fold when tau\(^{R406W}\) was expressed in a Trxr heterozygous or in a Sod2 heterozygous background (Figure 7E). Our results showed that oxidative stress can promote cell cycle activation and apoptosis in the brains of tau transgenic flies, thereby supporting the hypothesis that oxidative damage may promote neurodegeneration by enhancing tau-induced cell cycle activation. In addition, there were no signs of cell cycle activation in flies heterozygous for either Trxr\(^{Δ}\) or Sod2\(^{1}\), which were indistinguishable from age-matched controls as determined by PCNA immunostaining (Figure 7E). This observation suggested that, in our model, enhancement of cell cycle activation induced by oxidative damage resulted from a synergistic effect.

Phosphorylated histone 3 (PH3) is another cell cycle marker found to be aberrantly expressed in AD (21) and in tau transgenic flies but not in controls (35). To determine which cell type undergoes cell cycle induction in our model, brain sections from 10-day-old tau\(^{R406W}\) transgenic flies were costained with antibodies specific for PH3 and either the neuronal marker elav or the glial marker repo. This analysis revealed that PH3-positive cells also expressed antiactin (Figure 7E). The number of PH3-positive foci found in the brains of tau\(^{R406W}\) flies was increased by over 2-fold for tau\(^{R406W}\) flies expressing a pseu, Sod2, or Trxr (Figure 7C) or with repo (Figure 7D) or with a combination of Trxr and Sod2 (Figure 7E). These results showed a close correlation between JNK pathway activation and the degree of neurotoxicity associated with different tau transgenes. Furthermore, β-gal–positive staining was identified in cells that also expressed the neuronal cell marker elav (Figure 6, G–I) but not in repo-positive glial cells (Figure 6, J–L), suggesting that in our tauopathy model, JNK activation occurs mostly in neurons.
elav (Figure 7, F–H) but not repo (Figure 7, I–K). Although it is possible that some glial cells experience cell cycle reentry, these findings suggest that aberrant cell cycle reentry in our tauopathy model is, for the most part, a neuronal event.

**Discussion**

In this study, we provide substantial in vivo evidence supporting a causative role for oxidative stress in tau-induced neurodegeneration. It is well known that oxidative damage markers accumulate in tissue samples derived from patients with neurodegenerative disorders, such as AD and tauopathies (19, 20, 38), but whether this is a result of the disease process or whether oxidative stress actively induces neurodegeneration is still debated (17). Using a Drosophila model of human tauopathy, we show that genetic and pharmacological upregulation of antioxidant defenses significantly rescues neurotoxicity in the brains of tau transgenic flies (Figure 3). Conversely, genetic inactivation of antioxidant mechanisms enhances tau-induced neurodegeneration (Figures 1 and 2). These observations strongly implicate oxidative stress as a critical mediator of tau-induced neurotoxicity.

Despite significant effort, we were unable to detect clear changes in the levels of oxidative damage in the brains of tau-expressing flies compared with controls. Interestingly, Zheng et al. showed that even after an extremely strong oxidative challenge, immunohistochemical analysis only detected a very small increase in oxidized lipids in the brain proper of Drosophila (despite clear differences in the fat tissue adjacent to the brain) (39). These observations suggest a lack of sensitivity of conventional methodologies for measuring oxidative damage in the fly brain. Nevertheless, the fact that we were able to significantly rescue the neurodegenerative phenotype of tau transgenic flies by overexpression of 2 different enzymes with well-established antioxidant activities (Figure 3A) and by feeding with an
antioxidant (Figure 3B) suggests the presence of oxidative damage in our model. Whether the accumulation of oxidative damage over time is enhanced by tau overexpression remains unclear.

Although the accumulation of ROS causes oxidative stress, low to moderate levels of ROS are used under physiological conditions to regulate signaling pathways required for proper cell function. Similarly, reactive nitrogen species such as NO have oxidizing properties that can contribute to oxidative damage but also play important biological roles in processes that include neurotransmission and immune regulation (40). Overexpression of certain presenilin 1 (PS1) mutants linked to familial forms of AD in cultured neurons induces cell death that can be suppressed by NOS inhibitors (41). Consistent with the hypothesis that increased levels of NO contribute to AD pathogenesis, Nathan et al. reported that deletion of NOS2 in double-transgenic mice expressing mutant forms of amyloid precursor protein (APP) and PS1 protected against early mortality and decreased plaque formation (42). However, in a recent study, genetic removal of NOS2 was found to increase tau pathology and β-amyloid deposition in transgenic mice expressing mutant APP (43). These findings suggest that reducing the levels of NO can differentially affect AD pathology, depending on the genetic context, and may be a reflection of the dual role of reactive nitrogen species as both harmful and valuable.

Clinical trials using antioxidants and, more specifically, vitamin E yielded conflicting results regarding the suitability of this drug for the treatment of AD and other neurodegenerative diseases (31, 44, 45). Here, we show that administration of α-tocopherol (vitamin E) significantly suppressed tau-induced neurotoxicity in Drosophila (Figure 3B). As direct comparison of drug dosages between flies and humans is not feasible, our findings provide qualitative implications for the use of vitamin E in the treatment of human neurodegeneration. Interestingly, similar beneficial results were recently reported by others using transgenic mouse models of human tauopathies (46) and AD (47, 48). Taken together with these reports, our data underscore the therapeutic potential of vitamin E.

How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35). How might increased levels of oxidative stress enhance tau neurotoxicity? Given the importance of tau phosphorylation in promoting neurotoxicity (Steinhilb et al., unpublished observations; refs. 28, 29, 34, 35, 49), we first determined whether oxidative damage could influence tau phosphorylation. Our analysis suggests that oxidative stress does not act by promoting tau phosphorylation at major disease-associated sites because phosphorylation of tau is not altered in contexts of exacerbated oxidative stress (Figure 5A). Additionally, increased levels of oxidative stress can significantly enhance neurodegeneration associated with a kinase insensitive form of tau that is pseudophosphorylated at 14 SP/TP sites (Figure 28, 29, 34, 35).
tauopathies. Our results also suggest that oxidative injury enhances cell cycle activation and does not act to promote tau phosphorylation. Furthermore, we show that the JNK signaling pathway is activated in tau transgenic flies and that the levels of JNK activation correlate with the degree of tau-induced neurotoxicity. In summary, our results suggest that increased levels of oxidative stress play an active role in enhancing tau-mediated neurodegeneration, possibly through cell cycle activation, underscoring the therapeutic potential of targeting anti-oxidant pathways and cell cycle mechanisms for the treatment of AD and human tauopathies.

Methods

Drosophila stocks and genetics. Flies were grown on standard cornmeal-based Drosophila medium at 25°C. The UAS-tauWT, UAS-tauE206K, and UAS-tauE214 transgenic lines were previously described (27, 35). Panneuronal transgene expression was achieved using the elav-GAL4 driver. Drosophila lines expressing equivalent levels of tau transgenes in the brain were used. Two lines of tauE214-expressing flies were used, line 22 (Figure 5) and line 26 (Figure 6). In tauE214 flies, tau expression levels matched those of tauWT and tauE206K transgenic flies used in this study. The tauE214 flies transgenic flies expressed slightly higher levels of tau than tauE214 flies, which resulted in slightly higher levels of neurotoxicity.

Drug feeding. For vitamin E feeding (Figure 3), Drosophila were fed 0.5 mM or 1.5 mM of α-tocopherol (Sigma-Aldrich) that had been dissolved in soybean oil and mixed with standard cornmeal medium. Control flies grown in the absence of drug were fed standard cornmeal medium with 3% soybean oil solvent alone. Drug and control feeding trials were performed for 10 days after eclosion. Flies were transferred to fresh food every second day. For parquet feeding (Figure 4), flies were fed 30 mM of methyl violagen (Sigma-Aldrich) in instant Drosophila medium (Carolina). Control flies were fed instant medium only. One-day-old adult flies were kept in 30 mM parquat or in drug-free medium for 48 hours after eclosion.

Histology, immunostaining, and TUNEL analysis. Heads from adult flies fixed in formalin for 5 or 10 days after eclosion were embedded in paraffin and sectioned in a frontal orientation. Serial 4-μm sections spanning the whole brain were placed on a glass slide and subject to further analysis. Brain morphology was evaluated by staining paraffin sections with H&E according to standard protocols.

For immunostaining analysis on paraffin sections, antigen retrieval was achieved by boiling (15 minutes, 10 mM sodium citrate, pH 6.6). Immunostaining was performed using an avidin-biotin-peroxidase complex (ABC) method (VECTASTAIN ABC Kit; Vector Laboratories) or secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor 555 (Invitrogen). Primary antibodies included anti-active JNK (Promega; 1:300), anti-β-gal (Promega; 1:500), anti-elav (Developmental Studies Hybridoma Bank; 1:200), anti-PCNA (Biomeda; 1:500), anti-PH3 (Upstate; 1:300), anti-repo (Developmental Studies Hybridoma Bank; 1:200), anti–α-tocopherol (Sigma-Aldrich; 1:500), anti-elav-GAL4 (Promega; 1:500), anti-elav (Developmental Studies Hybridoma Bank; 1:200), anti–PCNA (Biomeda; 1:500), anti-PH3 (Upstate USA Inc.; 1:500), and anti–repo (Developmental Studies Hybridoma Bank; 1:250). The appropriate secondary antibodies were diluted 1:200, and histochemoical detection was done by developing with DAB (Sigma-Aldrich). Nuclei were counterstained with hematoxylin.

Apoptotic cell death was detected by TUNEL staining on paraffin sections according to the manufacturer’s instructions (TdT FragEL DNA fragmentation kit; Calbiochem; EMD Biosciences). Quantification of TUNEL-positive cells (Figures 2, 3, 5, and 6 and Supplemental Figure 2), β-gal-positive nuclei (Figure 6), PCNA-positive foci (Figure 7), and vacuoles with diameter greater than 3 μm (Figure 1 and Supplemental Figure 2) was performed by visually examining serial frontal sections (4 μm thick) spanning the entire fly brain. All positive occurrences identified in each hemibrain in the regions of the central body, the lobula, and the
medulla were manually scored (anatomic information on the fly brain can be found at Basic Atlas of the Drosophila Brain, http://web.neurobio.arizona.edu/Flybrain/html/atlas/index.html). In all graphs, each data point represents the average number of counts obtained for at least 8 hemibrains. The number of hemibrains used in each experiment was sufficient to account for the degree of variability among different samples and to yield highly significant results, noted by asterisks. Statistical analysis was performed using 1-way ANOVA with Student-Newman-Keuls post hoc test, and data points represent the mean ± SEM. Results were considered significant at P < 0.05.

Western blot. Heads from adult flies aged for 10 days after eclosion were homogenized in 2× Laemmli buffer, resolved by SDS-PAGE, and subjected to immunoblotting analysis using standard procedures. Primary antibodies and their respective dilutions were as follows: anti-AT8 (Pierce Biotechnology, 1:50,000), anti-AT100 (Pierce Biotechnology, 1:500), anti-AT180 (Innogenetics, 1:2,000), anti-TG3 (P. Davies, Albert Einstein College of Medicine, Bronx, New York, USA; 1:1,000), anti-PHF1 (P. Davies; 1:50,000), anti-Tau1 (Chemicon International; 1:2,000), anti-total tau (Dako, 1:1,000,000), and anti-actin (Sigma-Aldrich; 1:50,000). Prior to immunostaining with AT8 and TG3 antibodies, nitrocellulose membranes were boiled (5 minutes, 1× PBS) for antigen retrieval. HRP-conjugated secondary antibodies were used at a 1:50,000 dilution, and signal detection was performed with chemiluminescence (Pierce Biotechnology).

Acknowledgments

We thank F. Missirlis, H. Jackle, J. Phillips, H. Jasper, D. Bohmann, and the Drosophila stock center for providing fly lines; J. Locascio for statistical consultation; and V. Khurana for critical comments on the manuscript. TG3 and PHF1 monoclonal antibodies were kind gifts of P. Davies. This work was supported by NIH grants AG19790 and AG005134 (to M.B. Feany) and by a grant from the Portuguese Foundation for Science and Technology (FCT reference: SFRH/BPD/20685/2004; to D. Dias-Santagata).

Received for publication April 7, 2006, and accepted in revised form October 31, 2006.

Address correspondence to: Mel B. Feany, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Harvard New Research Building, Room 652, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. Phone: (617) 525-4405; Fax: (617) 525-4422; E-mail: mel_feany@hms.harvard.edu.